Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 53, 456-459, February 1, 1993]
© 1993 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bloemena, E.
Right arrow Articles by Vermorken, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bloemena, E.
Right arrow Articles by Vermorken, J. B.

Delayed-Type Hypersensitivity Reactions to Tumor-associated Antigens in Colon Carcinoma Patients Immunized with an Autologous Tumor Cell/Bacillus Calmette-Guérin Vaccine

Elisabeth Bloemena1, Helen Gall, Janet H. Ransom, Nicholas Pomato, James H. Murray, Ebo Bos, Rik J. Scheper, Chris J. L. M. Meijer, Michael G. Hanna, Jr. and Jan B. Vermorken

Departments of Pathology [E. B., R. J. S., C. J. L. M. M.] and Oncology [H. G., J. B. V.], Free University Hospital, Amsterdam, the Netherlands; Organon Teknika/Biotechnology Research Institute, Rockville, Maryland [J. H. R., N. P., J. H. M., M. G. H.]; and Organon International, Oss, the Netherlands [E. B.]

Five different colon tumor-associated antigens (CTAA) were tested for their ability to induce an immune response in vivo and in vitro in ten colon carcinoma patients immunized with an irradiated autologous tumor cell/Bacillus Calmette-Guérin vaccine (active specific immunization) after resection of the primary tumor. The CTAA were defined by two different human monoclonal antibodies (MCA 1688 and MCA 28A32) derived by immortalization of peripheral blood B-lymphocytes from an active specific immunization patient. Delayed-type cutaneous hypersensitivity responses against a mixture of CTAA 28A32-50K and -32K were positive in seven of ten patients tested. In vitro T-cell responses upon stimulation with CTAA 28A32-32K were found to be positive in seven of ten patients and correlated with delayed-type cutaneous hypersensitivity responses to the antigen mixture. These data suggest that CTAA 28A32-32K might contain an important tumor-related T-cell epitope. Moreover, this method is suitable to define potential future candidates for antitumor vaccine development.

1 To whom requests for reprints should be addressed, at Dept. of Pathology, Free University Hospital, de Boelelaan 1117, 1181 HV Amsterdam, the Netherlands.

Received 9/24/92. Accepted 12/14/92.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1993 by the American Association for Cancer Research.